A data-driven cartography of NSCLC vaccine research: Quantifying the paradigm shift toward immuno-oncology combination therapies
Authors:
Open Access
- 2 February 2026
- journal article
- review article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2615515
Abstract
The therapeutic vaccine landscape for non-small cell lung cancer (NSCLC) has evolved substantially over the past three decades, yet systematic analysis of this progression remains limited. We conducted bibliometric analysis of NSCLC vaccine research using 765 publications spanning 1990-2025 from Web of Science and Scopus databases. Our temporal analysis revealed a marked paradigm shift from early investigations on single-antigen approaches (particularly MAGE-A3) and specific platforms such as BLP25 liposome vaccines toward combination strategies integrating immune checkpoint inhibitors (ICIs) and advanced RNA vaccine technologies. This reflects reorientation from standalone vaccine modalities to synergistic approaches combining vaccines with established therapeutics, including ICIs, targeted therapies, and antibody-drug conjugates. This bibliometric analysis provides the first systematic mapping of NSCLC vaccine research evolution, revealing a clear trajectory toward combination immunotherapy strategies and offering an evidence-based framework for identifying research priorities and informing future development directions in cancer vaccine research.Keywords
Funding Information
- the National key research program (grant no. 2020YFC2005506)
This publication has 164 references indexed in Scilit:
- Update 2025: Management of Non‑Small-Cell Lung CancerLung, 2025
- BRAF in non–small cell lung cancer: From molecular mechanisms to clinical practiceCancer, 2025
- Targeting ROS1 rearrangements in non–small cell lung cancer: Current insights and future directionsCancer, 2025
- Treatment of non–small cell lung cancer with RET rearrangementsCancer, 2025
- Crosstalk between cancer and immune cells: Role of tumor‐associated macrophages in the tumor microenvironmentCancer Medicine, 2019
- A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancerCancer Immunology, Immunotherapy, 2019
- CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literatureJournal of the American Society for Information Science and Technology, 2005
- A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late‐stage lung carcinomaCancer, 2005
- Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancerThe Journal of Gene Medicine, 2003
- Effect of interleukin-8 on production of tumor-associated substances and autocrine growth of human liver and pancreatic cancer cellsCancer Immunology, Immunotherapy, 1998